$1.04
-0.13 (-11.11%)
Open$1.14
Previous Close$1.17
Day High$1.22
Day Low$1.00
52W High$43.61
52W Low$20.38
Volume—
Avg Volume334.5K
Market Cap47.69M
P/E Ratio—
EPS$-1.69
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+4,089.4% upside
Current
$1.04
$1.04
Target
$43.57
$43.57
$34.30
$43.57 avg
$49.66
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 9.29M | 9.20M | 8.70M |
| Net Income | -2,793,034 | -2,830,498 | -1,987,756 |
| Profit Margin | -30.1% | -30.8% | -22.8% |
| EBITDA | -2,857,375 | -2,581,372 | -2,786,589 |
| Free Cash Flow | -3,645,818 | -3,568,526 | -2,022,520 |
| Rev Growth | +3.0% | +9.2% | +11.7% |
| Debt/Equity | 0.31 | 0.31 | 0.36 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |